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Abstract
As part of this thematic series on mitochondria in cell death, we would like to review our data on: (1) the role of the
mitochondrial permeability transition (MPT) in hepatocyte necrosis during cholestasis ; and (2) the concept that endogenous
mitochondrial protease activity may lead to the MPT. Many chronic human liver diseases are characterized by cholestasis, an
impairment in bile flow. During cholestasis an accumulation of toxic hydrophobic bile salts in the hepatocyte causes necrosis.
We tested the hypothesis that toxic hydrophobic bile salt, glycochenodeoxycholate (GCDC), causes hepatocyte necrosis by
inducing the MPT. GCDC induces a rapid, cyclosporin A-sensitive MPT. The hydrophilic bile salt, ursodeoxycholate
(UDCA), prevents the GCDC-induced MPT and hepatocyte necrosis providing an explanation for its beneficial effect in
human liver disease. We have also demonstrated that the calcium-dependent MPT is associated with an increase in calpain-
like protease activity and inhibited by calpain inhibitors. In an experimental model of cholestasis, mitochondrial calpain-like
protease activity increases 1.6-fold. We propose for the first time that activation of mitochondrial proteases may initiate the
MPT and cell necrosis during cholestasis. ß 1998 Elsevier Science B.V. All rights reserved.
Keywords: Bile salt ; Bile duct-ligated rat; Cytoprotection; Cbz-Leu-Leu-Tyr-CHN2 ; tert-Butylhydroperoxide; Ursodeoxycholate
1. Cholestatic liver disease and mitochondrial
dysfunction
Chronic cholestasis is a feature of many human
liver diseases including primary sclerosing cholangi-
tis, primary biliary cirrhosis, biliary atresia, and
chronic allograft rejection. During cholestasis, best
de¢ned as an impairment in bile £ow, toxic hydro-
phobic bile salts, sterol derived compounds synthe-
sized and secreted by the liver into bile during health,
accumulate in the hepatocyte [1]. The accumulation
of toxic hydrophobic bile salts is thought to cause
hepatocyte necrosis contributing to the pathogenesis
of the cholestatic disease process [2]. The importance
of bile salt-induced hepatocyte injury is highlighted
by the clinical observation that exogenous adminis-
tration of ursodeoxycholate (UDCA), a hydrophilic
bile salt, ameliorates liver injury during cholestasis
[3]. However, the subcellular mechanisms by which
toxic hydrophobic bile salts cause hepatocyte ne-
crosis or how ursodeoxycholate exerts its cytoprotec-
tive e¡ects remain obscure.
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Several studies suggest that bile acids may be cy-
totoxic by causing mitochondrial dysfunction. First,
enlarged, swollen mitochondria are observed in his-
topathologic sections obtained from bile duct ligated
rats (a model of extrahepatic cholestasis) with cho-
lestatic liver diseases [4,5]. Second, mitochondria iso-
lated from bile duct ligated rats have impaired state
III respiration [6]. The impairment of state III respi-
ration can be duplicated by exposing mitochondria
or permeabilized hepatocytes to bile salts [7,8]. Fi-
nally, we have demonstrated that ATP depletion oc-
curs early during exposure of hepatocytes to necrotic
concentrations of toxic bile salts [7]. The ATP deple-
tion is directly due to mitochondrial dysfunction as
glycolytic ATP generation is intact. Thus, as assessed
using both morphologic and biochemical parameters,
mitochondrial function is perturbed by cholestasis or
exposure to toxic bile salts, suggesting that toxic bile
salts cause hepatocyte injury via a mitochondrial-de-
pendent mechanism.
Current concepts implicate the mitochondrial
membrane permeability transition (MPT) as the
cause of hepatocyte necrosis mediated by mitochon-
drial dysfunction [9,10]. The MPT is characterized by
a rapid permeability of the inner mitochondrial
membrane to ions associated with mitochondrial
swelling and a collapse of the mitochondrial mem-
brane potential [11]. Cell necrosis by the MPT is
thought to occur by the opening of a ‘mega channel’
in the inner mitochondrial membrane causing an in-
crease in mitochondrial permeability to small molec-
ular mass compounds, 6 1500 Da [11]. Cyclosporin
A inhibits the opening of this pore, an e¡ect which is
enhanced by tri£uoperazine [12], and these agents
prevent hepatocyte necrosis in many models of cell
death [10].
Despite its appreciable scienti¢c and clinical im-
portance, the ability of toxic bile salts to induce the
MPT has not been studied. Thus, we ¢rst sought
to answer the following questions. Does the toxic
hydrophobic bile salt, glycochenodeoxycholate
(GCDC), induce the MPT in isolated rat liver mito-
chondria? Does UDCA and/or its taurine and glyc-
ine conjugates prevent the MPT induced by GCDC
and other agents? We chose GCDC as the toxic
hydrophobic bile salt for these studies because it
is a primary bile salt whose concentrations in-
crease s 20-fold during cholestasis [1].
1.1. Experimental procedure section for bile salt
induction of the MPT
1.1.1. Isolation of rat liver mitochondria and
measurement of the mitochondria
permeability transition
Liver mitochondria were isolated from adult male
Sprague-Dawley rats (250^350 g) as previously de-
scribed by us in detail with minor modi¢cations
[13]. We modi¢ed the procedure by adding digitonin
to the percoll-sucrose gradient to deplete mitochon-
dria of lysosomes. At low concentrations, digitonin
abolishes lysosomal latency without a¡ecting mito-
chondrial integrity [14]; therefore, digitonin can be
used to deplete mitochondria of lysosomes [14]. We
used a digitonin containing gradient to remove lyso-
somes from our mitochondrial preparation. A su-
crose-percoll solution was prepared by mixing 75
ml of 250 mM sucrose containing 1 mM EGTA
and 50 WM digitonin plus 25 ml of percoll (density
1.129 g/ml); a self-generating gradient was obtained
by centrifuging 35 ml of the sucrose-percoll solution
at 43 000Ug for 20 min at 4‡C in 50 ml polycarbon-
ate tubes prior to layering on the mitochondrial sus-
pension [13]. Mitochondria were puri¢ed by centrifu-
gation at 43 000Ug for 20 min at 4‡C using a
Beckman Centrifuge Model J2-21 M/E and JA 20
rotor. The mitochondrial pellet was washed free of
percoll as previously described and resuspended in 2^
3 ml of a bu¡er containing 125 mM sucrose, 50 mM
KCl, 5 mM HEPES, and 2 mM KH2PO4, pH 7.4
[13]. The purity of the mitochondria preparation was
established using marker enzymes and transmission
electron microscopy [13].
The MPT was measured spectrophotometrically as
previously described [15]. Isolated rat liver mitochon-
dria were suspended in a bu¡er consisting of 200
mM sucrose, 10 mM Tris-MOPS, 5 mM succinate,
1 mM KH2PO4, 2 WM rotenone, 1 Wg/ml oligomycin,
10 WM EGTA, pH 7.4 at 25‡C [15]. The optical den-
sity was monitored at 540 nm in a Beckman DU
7400 Diode Array Spectrophotometer (Beckman In-
struments, Palo Alto, CA) at 25‡C.
1.2. Does glycochenodeoxycholate (GCDC) induce
the MPT in isolated rat liver mitochondria?
GCDC induced high amplitude mitochondrial
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swelling which was both rapid (occurring within
5 min) and dose dependent (0^500 WM) [13]. Because
GCDC concentrations of 200 WM are relevant to
cholestatic liver injury and induced a rapid and sub-
stantial MPT, we used this concentration of GCDC
for further studies (Fig. 1). In contrast to the results
with GCDC, the hydrophilic bile salts ursodeoxycho-
late (UDCA), tauroursodeoxycholate (TUDC) and
glycoursodeoxycholate (GUDC) at concentrations
of 200 WM did not induce the MPT (Fig. 1). Tri£uo-
perazine (10 WM) plus cyclosporin A (5 WM) also
inhibited mitochondrial swelling caused by 200 WM
GCDC (Fig. 2) demonstrating that the GCDC-in-
duced MPT was cyclosporin A sensitive. These
data directly demonstrate that the hydrophobic bile
salt GCDC, but not the hydrophilic bile salt UDCA
and its conjugates, induce a cyclosporin-sensitive
MPT.
1.3. Does ursodeoxycholate (UDCA) inhibits the
GCDC-induced MPT and hepatocyte necrosis?
Because of UDCA’s therapeutic bene¢ts in human
cholestatic liver diseases, we next tested the hypoth-
esis that UDCA exerts its bene¢cial e¡ects by inhib-
iting the MPT induced by hydrophobic bile salts.
Indeed, UDCA inhibited the GCDC-induced MPT
in a dose-dependent fashion with maximum inhibi-
tion at 500 WM [13]. Pretreatment of the mitochon-
dria for 5 min with 500 WM UDCA inhibited the
GCDC-induced MPT by 69.7 þ 0.2% (Fig. 3). In ad-
dition to blocking the MPT in isolated mitochondria,
UDCA strongly protected against the onset of hep-
atocyte necrosis during incubation with GCDC (Ta-
ble 1). Hepatocyte viability was increased more than
2-fold in the presence of 500 WM UDCA plus 250
WM GCDC compared to cells incubated with GCDC
alone. Cytoprotection by UDCA could not be attrib-
uted to displacement of intracellular GCDC with
UDCA as intracellular accumulation of 24-14C-
GCDC was virtually identical in the presence or ab-
sence of a 2-fold excess of unlabeled UDCA
Fig. 1. GCDC, but not UDCA or its taurine (TUDC) or glyc-
ine (GUDC) conjugate, induces the MPT. Isolated mitochon-
dria (1 mg protein/ml) were suspended in respiration bu¡er at
25‡C. Large amplitude swelling of suspended mitochondria was
measured by monitoring the optical density at 540 nm. At time
zero, the bile salts were added at concentrations of 200 WM and
mitochondrial swelling was monitored for an additional 5 min.
Fig. 2. Cyclosporin A (CyA) plus tri£uoperazine (TFP) inhibit
the GCDC-induced MPT. Isolated mitochondria (1 mg protein/
ml) were suspended in respiration bu¡er at 25‡C and preincu-
bated for 5 min with 5 WM CyA, 10 WM TFP or 5 WM CyA
plus 10 WM TFP. At time zero, 200 WM GCDC was added and
mitochondrial swelling was monitored for an additional 5 min.
Fig. 3. UDCA inhibits the GCDC-induced MPT. Isolated mito-
chondria (1 mg protein/ml) were suspended in respiration bu¡er
at room temperature and preincubated for 5 min with UDCA
(500 WM). At time zero, 200 WM GCDC was added and mito-
chondrial swelling was monitored for an additional 5 min.
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(1.07 þ 0.02 vs. 1.13 þ 0.02 14C pmol/106 cells). If the
MPT is a mechanism of GCDC-mediated hepatocyte
necrosis then cyclosporin A plus tri£uoperazine
(well established inhibitors of the MPT) should also
protect against GCDC mediated cytotoxicity. In-
deed, cyclosporin A (5 WM) plus tri£uoperazine
(10 WM) also protected against cell death by
250 WM GCDC (Table 1). Hepatocyte viability was
approx. 4-fold greater in the presence of cyclosporin
A plus tri£uoperazine during treatment with 250 WM
GCDC. These observations suggest that GCDC-in-
duced cytotoxicity is due to mitochondrial dysfunc-
tion with development of the MPT. Furthermore,
these data suggest for the ¢rst time an intracellular
pharmacologic mechanism for UDCA cytoprotec-
tion, namely, inhibition of the MPT by toxic bile
salts.
2. Calpain-like protease activity and the MPT
Toxic hydrophobic bile salts are amphipathic mol-
ecules that can promote calcium £ux across biomem-
branes, liposomes and synthetic membranes [16].
Moreover, GCDC-mediated hepatocyte necrosis is
associated with increases of intracellular calcium
[7]. Like many models of calcium cytotoxicity,
GCDC-mediated hepatocyte necrosis is also inhib-
ited by an acidic pH [7]. The calcium and pH de-
pendence of GCDC-mediated hepatocyte necrosis
corresponds to the calcium and pH dependence of
the MPT and in this regard is consistent with the
MPT as a mechanism of hepatocyte necrosis. How-
ever, the calcium and pH dependence of GCDC-
mediated cell killing is also consistent with cell killing
by calpains, cytoplasmic, calcium-dependent, neutral,
cysteine proteases [17,18]. Indeed, several studies
have implicated calpain-like protease activity in cell
necrosis [9]. Therefore, we proposed a novel hypoth-
esis to reconcile these observations. Our hypothesis is
that a mitochondrial calpain-like protease activity
can mediate the MPT. In support of this hypothesis
is the observation that mitochondria have been re-
ported to contain a calcium-dependent protease ac-
tivity analogous to the calpains [19,20]. Thus, using
the substrates and inhibitors used to identify the in-
crease in calpain-like protease activity in cell ne-
crosis, we performed experiments to answer the fol-
lowing two questions. (1) Do rat liver mitochondria
contain a calcium-dependent, calpain-like protease
activity? (2) Can mitochondrial protease activity in-
duce the MPT in isolated mitochondria?
2.1. Experimental procedure section for determination
of calpain-like protease activity in mitochondria
2.1.1. Measurement of calpain-like protease activity in
mitochondria
Calpain-like protease activity was assayed by incu-
bating mitochondria (1 mg/ml) in isolation media
using the £uorogenic substrate Suc-Leu-Leu-Val-
Tyr-AMC [21]. Fluorescence was monitored in mito-
chondrial suspensions following the addition of Suc-
Leu-Leu-Val-Tyr-AMC in a £uorometer (Model LS-
50, Perkin-Elmer, Norwalk, CT) using excitation and
emission wavelengths of 380 and 460 nm respec-
tively. Standard curves were generated using AMC.
All experiments were performed at 25‡C.
2.1.2. Measurement of mitochondrial membrane
potential in hepatocytes
Rat hepatocytes were isolated in suspensions and
cultured as we have previously described in detail [7].
Experiments measuring the mitochondrial membrane
potential were performed using a multiparameter
digitized video microscopy (MDVM) system employ-
ing the Meta£uor quantitative £uorescence software
package from Universal Imaging (West Chester, PA)
[22]. The mitochondrial membrane potential was
monitored in single cultured hepatocyte, using the
membrane potential sensitive dye TMRE as we
Table 1
UDCA and cyclosporin/tri£uoperazine (CYA/TFP) inhibit cell
necrosis by GCDC
Treatment Cell viability (%)
Control 83 þ 3
GCDC 17 þ 2
GCDC+UDCA 49 þ 6
GCDC+CYA/TFP 68 þ 4
Rat hepatocyte suspensions (105/ml) were incubated in 3 ml of
Krebs-Ringer-HEPES bu¡er at 37‡C for 4 h. Cell viability was
measured by propidium iodide £uorometry [7]. GCDC was
used at a concentration of 250 WM, UDCA at a concentration
of 500 WM, and cyclosporin plus tri£uoperazine at concentra-
tions of 5 WM and 10 WM, respectively.
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have previously described in detail [22]. Brie£y, cells
were loaded with TMRE on the microscope stage by
incubation in Krebs-Ringer-HEPES bu¡er (KRH
bu¡er) containing 50 nM TMRE for 15 min at
37‡C and then incubated in the presence of 50 nM
TMRE throughout the experiment. Cellular £uores-
cence was quantitated by multiplying the average
£uorescence intensity in the cell by the number
of pixels above background using a threshold of
zero.
2.2. Do mitochondria contain a calpain-like protease
activity?
Mitochondria hydrolyzed the £uorogenic substrate
in a Ca2-dependent manner. Mitochondrial hydrol-
ysis of Suc-Leu-Leu-Val-Tyr-AMC was minimal in a
calcium containing medium in the absence of a cal-
cium ionophore, 0.7 þ 0.1 pmol AMC (mg protein)31
min31, but increased more than 9-fold in the pres-
ence of 50 WM 4-Br-A23187 (a non-£uorescent cal-
cium ionophore) to 6.5 þ 0.2 pmol AMC (mg
protein)31 min31. The Km for the rate of hydrolysis
was approx. 35 þ 4 WM. The location of the protease
activity in the mitochondria was determined by frac-
tionating the mitochondria into outer membrane, in-
termembrane space, inner membrane, and matrix
components using the methodology validated and
established by Greenawalt and co-workers [23]. The
protease activity was found to be largely in the in-
termembrane space (Fig. 4), a position which may
allow it to modify the external domains of proteins
forming the permeability transition pore within the
inner membrane. More importantly, however, we ob-
served a 1.6-fold increase in mitochondrial calpain-
like activity in mitochondria isolated from the bile
duct ligated rat, an animal model of extrahepatic
cholestasis relevant to human cholestatic liver dis-
ease. These data demonstrate that mitochondria do
contain a calpain-like protease activity which in-
creases in cholestasis. Dubiel and co-workers have
also previously described a mitochondrial protease
in the intermembrane space which recognizes Suc-
Leu-Leu-Val-Tyr-AMC as a substrate [24]. It is likely
that our protease and the protease activity described
by this group are the same protease. However, the
protease has not been puri¢ed nor cloned and thus
its identi¢cation remains unknown.
2.3. Cysteine protease inhibitors block the
calcium-induced MPT in isolated mitochondria
We next determined whether cysteine protease in-
hibitors would prevent mitochondrial hydrolysis of
the £uorogenic substrate. Inhibition of hydrolysis
of Suc-Leu-Leu-Val-Tyr-AMC was speci¢c for cys-
teine protease inhibitors (leupeptin, E-64, calpain in-
hibitor 1, and Cbz-Leu-Leu-Tyr-CHN2) whereas the
serine (3,4-dichloroisocoumarin), aspartate (pepsta-
tin) and metalloprotease (1,10-phenanthroline) inhib-
itors did not inhibit hydrolysis of the £uorogenic
substrate [15]. Thus, the mitochondrial protease ac-
tivity appeared to be a calpain-like protease because
it recognized a calpain substrate, and was inhibited
by a calpain protease inhibitor. However, further
de¢nition of this protease including its ion depend-
ence, pH dependence, and preferred substrate will
depend upon isolation and identi¢cation of the pro-
tease.
Preincubation of the mitochondria with the cys-
Fig. 4. The mitochondrial calpain-like protease activity is lo-
cated in the intermembrane space. Mitochondria from rat liver
were puri¢ed by percoll gradient centrifugation. The mitochon-
dria were then further fractionated into outer membrane, inter-
membrane space, inner membrane and matrix components us-
ing an established technique employing the detergents digitonin
and lubrol and ultracentrifugation procedures. The protease ac-
tivity was measured in each fraction using the £uorogenic sub-
strate Suc-Leu-Leu-Val-Tyr-AMC (50 WM).
BBABIO 44655 30-7-98
G.J. Gores et al. / Biochimica et Biophysica Acta 1366 (1998) 167^175 171
teine protease inhibitors, Cbz-Leu-Leu-Tyr-CHN2,
leupeptin and E-64, inhibited the Ca2-induced
MPT (Fig. 5). Cbz-Leu-Leu-Tyr-CHN2 was the
most potent inhibitor of the MPT with maximum
inhibition of 82 þ 2% at 100 WM (Fig. 5). Moreover,
the highly speci¢c calpain inhibitors Z-Leu-Phe-
CONHEt (CX269) and Z-Leu-norvaline-CONH-
(CH2)3-morpholine (CX349) obtained from Dr. D.
Eveleth (Cortex Pharmaceuticals, Irvine, CA) also
inhibited the calcium-induced MPT (Fig. 6). Inhibi-
tion of the MPT by protease inhibitors was speci¢c
for cysteine protease inhibitors as the serine protease
inhibitor, TLCK, did not inhibit the Ca2-induced
MPT (Fig. 6). These protease inhibitors also blocked
induction of the MPT by 100WM tert-butylhydroper-
oxide (data not shown). The ability of leupeptin to
inhibit the MPT induced by tert-butylhydroperoxide
has also been observed by others [25]. Because these
protease inhibitors react with cysteine residues, we
cannot exclude the possibility that these inhibitors
are also reacting with thiols present in the MPT
pore. The role of this mitochondrial protease in me-
diating opening of the pore can only be rigorously
tested once it has been isolated and cloned; this work
is ongoing in our laboratory.
2.4. Does the calpain-selective protease inhibitor,
Cbz-Leu-Leu-Tyr-CHN2, delay mitochondrial
depolarization, a marker of the MPT, in
hepatocytes?
Finally, we sought to determine whether we could
extrapolate our results in isolated mitochondria to
the MPT in intact hepatocytes. We used the selective
calpain protease inhibitor Cbz-Leu-Leu-Tyr-CHN2
to determine whether it would prevent mitochondrial
depolarization in intact cells. The mitochondrial
membrane potential was measured as a surrogate
marker for the MPT in cultured cells [26]. We chose
tert-butylhydroperoxide (tBH) for these studies be-
cause it has been demonstrated to induce the MPT
in hepatocytes [26], and we wanted to test our hy-
pothesis in an established model before embarking
on experiments with toxic bile salts. As reported by
others, during exposure to 25 WM tBH, the mito-
chondrial membrane potential decreased to 54 þ 3%
of the initial value after 1 h of incubation. However,
the membrane potential was maintained in the pres-
ence of 100 WM Cbz-Leu-Leu-Tyr-CHN2 during
treatment with tBH [15]. Thus, inhibition of cal-
pain-like protease activity appears to inhibit the on-
set of the MPT in hepatocytes.
3. Summary
Our studies are important for the following three
Fig. 6. The cysteine protease inhibitors, leupeptin and E-64, but
not the serine protease inhibitor, TLCK, inhibit the Ca2-in-
duced MPT. Isolated mitochondria (1 mg protein/ml) were sus-
pended in a sucrose-based bu¡er at 25‡C. After 15 min of pre-
incubation in the presence of the protease inhibitors, calcium
(100 WM) was added and mitochondrial swelling was monitored
for an additional 10 min.
Fig. 5. The cysteine protease inhibitors, Cbz-Leu-Leu-Tyr-
CHN2; CX269, and CX349, inhibit the Ca2-induced MPT. Iso-
lated mitochondria (1 mg protein/ml) were suspended in a su-
crose-based bu¡er at 25‡C. After 15 min of preincubation in
the presence of the protease inhibitors, calcium (100 WM) was
added and mitochondrial swelling was monitored for an addi-
tional 10 min.
BBABIO 44655 30-7-98
G.J. Gores et al. / Biochimica et Biophysica Acta 1366 (1998) 167^175172
observations. First, our results demonstrate for the
¢rst time that toxic bile salts can induce the MPT, an
observation relevant to hepatocyte injury during cho-
lestasis. Second, the results suggest that pharmaco-
logic agents such as ursodeoxycholic acid may exert
their cytoprotective properties by inhibiting the
MPT. Finally, our results suggest a provocative hy-
pothesis, namely, that mitochondrial protease activ-
ity may produce the MPT under pathophysiologic
conditions.
Bile salts have been previously demonstrated to
cause mitochondrial dysfunction with impairment
of oxidative phosphorylation [6,8]. Our data further
extend these observations by demonstrating induc-
tion of the MPT by toxic bile salts. Because the
MPT has been implicated as a mechanism of cell
necrosis and apoptosis [10], our observations provide
a mechanism for hepatocellular injury during choles-
tasis. Our observations of the MPT in isolated mito-
chondria also provide an explanation for the large,
swollen mitochondria observed in histopathologic
specimens from animals with cholestasis [4]. The
mechanism by which bile salts induce the MPT re-
main unclear but may involve calcium £uxes into the
mitochondria. Bile salts promote calcium £ux across
biomembranes and increase cytosolic free calcium
[16]. Because increases of mitochondrial calcium
can promote the MPT [10], it appears likely that
the bile salt-induced MPT may be calcium mediated.
Further experimentation will be required to test this
hypothesis.
UDCA protected against induction of the MPT by
the toxic hydrophobic bile salt GCDC. The protec-
tive e¡ect of UDCA is not due to a simple biophys-
ical interaction between a hydrophobic and a hydro-
philic bile salt in the soluble phase or in the lipid
membrane as an equally hydrophilic bile salt, hyo-
deoxycholate, did not prevent the GCDC-induced
MPT (data not shown) [13]. The mechanism by
which UDCA prevents the GCDC-induced MPT re-
mains unclear. However, UDCA does not merely
antagonize the e¡ect of GCDC on inducing the
MPT, but appears to be an inhibitor of the MPT.
For example, UDCA prevents induction of the MPT
by phenylarsine oxide and mitochondrial depolariza-
tion in a number of models of hepatocyte apoptosis
[13,27]. UDCA would appear to be the ¢rst ap-
proved drug to work by such a mechanism.
An epithelial serine protease has been shown to
indirectly modulate the activity of the amiloride-sen-
sitive sodium channel [28]. Furthermore, Kroemer
and co-workers have demonstrated that caspase 1
can directly induce the MPT in isolated mitochon-
dria [29]. Thus, there is a precedent for protease
modulation of ion channels and the MPT. Our
data are consistent with the interpretation that an
endogenous mitochondrial protease may induce the
MPT. There are ¢ve conceptual mechanisms by
which calpain-like proteases could lead to the
MPT: (a) limited proteolysis of a channel protein
causing opening of the channel; (b) proteolysis of
proteins whose peptide fragments bind to channel
proteins inducing conformational changes and open-
ing of the channel; (c) proteolysis of a protein which
normally inhibits opening of the channel; (d) pro-
teolysis of proteins with the release of amphipathic
peptides which directly insert into the inner mem-
brane forming channels; and (e) proteolysis of struc-
tural proteins within the mitochondria which lead to
topographical disorganization of the mitochondria
and permeability changes. Current concepts suggest
the low conductance state of the MPT is reversible in
isolated mitochondria [30]. If the MPT is reversible
during cell injury, we ¢nd it unlikely that calpain-like
proteases cause pore opening by direct proteolytic
cleavage of channel proteins or proteolysis of mito-
chondrial structural proteins. Indeed, the serine pro-
tease activating the amiloride-sensitive sodium chan-
nel does so through an indirect mechanism that does
not involve proteolytic cleavage of the channel pro-
tein [28]. Proteolytic cleavage of bacterial toxins have
been shown to release peptide fragments with chan-
nel forming properties [31]; thus, it is conceivable
that this mechanism of channel formation (i.e., pro-
teolytic generation of amphipathic peptide fragments
which insert into the inner membrane of mitochon-
dria forming channels) could occur during cell dam-
age. However, this mechanism of pore formation
would not be consistent with the speci¢c e¡ects of
cyclosporin A as an inhibitor of pore opening. Pep-
tide fragments generated from proteolytic cleavage of
proteins could potentially reversibly bind to channel
proteins modulating opening and closing of the
channel. Indeed, mastoparan, a 14 amino acid am-
phipathic peptide, has been found to induce the MPT
[32]. Pfei¡er and co-workers have hypothesized that
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positively charged peptide fragments may allosteri-
cally modulate pore opening by binding at a site
which normally binds cations [32]. Finally, the hy-
pothesis that a protease could cleave an endogenous
inhibitor of the MPT also remains a tenable hypoth-
esis. Once the components forming the channel me-
diating the MPT are known, the mechanisms leading
to the MPT by calpain-like protease activity can be
directly elucidated. We believe it is highly likely that
numerous mechanisms will be shown to cause the
MPT including protease-dependent processes.
Our current work re£ects a hypothesis in evolu-
tion, an we realize that the data for our model re-
quire further evidence to be compelling. At this time,
our working hypothesis is that during cholestasis
there is an accumulation of toxic hydrophobic bile
salts within the hepatocyte. These bile salts promote
increases in cytosolic free calcium and mitochondrial
calcium resulting in an increase of mitochondrial cal-
pain-like protease(s) activity. We invoke increases in
calcium as the mediator for the protease activation
because: (i) we have directly observed an increase in
cytosolic calcium in Fura-2 loaded hepatocytes
treated with GCDC [7]; and (ii) GCDC itself does
not directly activate the mitochondrial protease ac-
tivity (data not shown). Following protease activa-
tion, we speculate that the protease activity then acts
on key inner membrane associated proteins leading
to formation of the mitochondrial transition pore.
The MPT would then result in failure of oxidative
phosphorylation, enhanced generation of toxic oxy-
gen species, a decrease in cellular ATP, release of
mitochondrial constituents leading to activation of
caspases, and perhaps other deleterious e¡ects on
the cell [9]. These adverse e¡ects of mitochondrial
dysfunction would then culminate in hepatocyte
death. Our data suggest a unifying hypothesis linking
the independent observations that mitochondrial
protease activity and the MPT are important mech-
anisms causing cell necrosis. We propose for the ¢rst
time that activation of mitochondrial calpain-like
protease activity can function as a cytolytic trigger
initiating the MPT in cell necrosis during cholestasis.
The identity of the protease, its substrates and why it
is increased in cholestatic liver disease are active
areas of investigation in our laboratory based re-
search program.
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